Carotid Intervention Selection, Timing, and Peri-Procedural Management

30.1Definition and presentation

Carotid stenosis is managed to prevent stroke; prevention is secondary after an attributable retinal or cerebral event and primary in asymptomatic disease. The primary distinction guiding intervention is whether the disease is symptomatic or asymptomatic. Symptomatic disease is defined by recent events in the ipsilateral territory:

• Ischemic stroke
• Transient ischemic attack
• Retinal ischemic event

Intervention requires an appropriate indication, not stenosis alone. For conventional symptomatic NASCET stenosis, benefit is clearest at 70 to 99% and more selective at 50 to 69%; near-occlusion and complete occlusion require separate assessment. For asymptomatic disease, the SVS ≥70% framework and the ESVS selected 60 to 99% framework are not identical. Apply the named guideline’s selection and survival requirements alongside contemporary trial results rather than using one universal cutoff. ESVS 2023 · AbuRahma et al. (2022) · NASCET · 1991 · Medical Management 2026 · NASCET 1998 The certainty of benefit decreases when a competing stroke mechanism is identified, such as atrial fibrillation, small-vessel disease, or dissection. Extracranial carotid disease indicates systemic atherosclerosis, and optimal medical therapy, including antiplatelet agents, statins, and blood-pressure control, is the baseline requirement for all patients, whether managed surgically or conservatively AHA/ASA 2021 · ESC 2017.

30.2Timing and intervention thresholds

Procedural safety is necessary but does not by itself establish benefit. Report independently assessed 30-day stroke-or-death outcomes, separately from in-hospital outcomes. The ESVS thresholds are <6% for symptomatic intervention and ≤3% for selected asymptomatic intervention. ESVS 2023

For suitable symptomatic patients, expedite CEA, ideally within 14 days. SVS’s stable-stroke pathway specifies mRS 0 to 2, neurological stability after 48 hours and treatment before 14 days; this is not a mandatory wait after every TIA. AbuRahma et al. (2022)

ESVS distinguishes two additional pathways. Consider urgent CEA, preferably within 24 hours, in selected patients with 50 to 99% stenosis and crescendo TIAs or stroke in evolution (IIa, C). Defer intervention with disabling stroke (mRS ≥3), infarction exceeding one-third of the ipsilateral MCA territory or altered consciousness (I, C), and reassess recovery and haemorrhagic risk. Recurrent transient events, an evolving deficit and extensive established injury must not be collapsed into a single “unstable” category. ESVS 2023

In asymptomatic disease, intervention lacks the urgency of a post-event window. Prophylactic intervention is scheduled electively only after risk factors are optimized and life-limiting comorbidities are assessed to ensure the patient will survive long enough to realize a long-term benefit ESVS 2023 · AbuRahma et al. (2022).

30.3Modality selection

Treatment modality balances patient age, surgical risk, and cervical and arch anatomy. Carotid endarterectomy (CEA) is the standard reference procedure for suitable candidates, while transfemoral carotid artery stenting (CAS) and transcarotid artery revascularization (TCAR) provide alternatives for specific anatomic or physiological challenges. Antiplatelet planning is described once below under Peri-procedural management.

The intervention decision follows an ordered sequence:

1. Confirm symptom attribution, NASCET stenosis category and the applicable indication; use the asymptomatic selection framework above rather than a universal ≥70% rule.
2. Ensure best medical therapy is established.
3. Determine if the operator and centre meet the stringent 30-day stroke-or-death safety thresholds.
4. Select CEA, CAS, or TCAR based on cervical access, arch anatomy, and physiological risk through shared decision-making. Discuss stroke/death, myocardial infarction and cranial nerve injury trade-offs and the uncertainty of observational TCAR comparisons; elicit the patient's values, understanding of the options and desired involvement in the decision. Three-year risk 2025 · Patient decision-making 2024 · Seven years 2024
5. Apply the distinct timing pathways above; assess neurological injury, survival, procedural risk and patient preferences rather than treating all neurological instability as a contraindication.

Peri-procedural management

CEA does not universally require either monotherapy or DAPT. For recently symptomatic patients with 50 to 99% stenosis scheduled for CEA, agree a local perioperative regimen without delaying urgent surgery; ESVS supports considering combination therapy after intracranial haemorrhage is excluded and also provides a monotherapy pathway. When aspirin monotherapy is used for CEA, 75 to 325 mg daily is recommended rather than doses >325 mg. For recently symptomatic 50 to 99% stenosis when monotherapy is preferred, ESVS also suggests considering aspirin 300 to 325 mg daily for 14 days, followed by 75 to 162 mg daily. CAS requires aspirin 75 to 325 mg plus clopidogrel 75 mg daily, with clopidogrel for at least three days beforehand or a 300 mg urgent loading dose; continue both for at least four weeks, then long-term single-agent therapy. ESVS prefers clopidogrel for long-term therapy after symptomatic CAS. Apply the stent antiplatelet requirement to TCAR with the device instructions and patient-specific bleeding assessment. ESVS 2023 · ENROUTE 2026

For conventional CEA, patch closure is preferred to routine primary closure; eversion CEA is a different reconstruction. Trial synthesis suggests reductions in ipsilateral stroke and restenosis with patching, but the evidence is low or very low certainty and does not establish a reduction in every perioperative stroke endpoint. ESVS 2023 · Patch angioplasty 2022 Watch for cranial nerve injury, most often the hypoglossal, the vagus or its recurrent laryngeal branch, and the marginal mandibular branch of the facial nerve. Clinically evident injury occurs in roughly 5 to 8% and resolves in most cases.

Strict blood-pressure control is required after any carotid revascularization. Cerebral hyperperfusion syndrome presents with ipsilateral headache, seizure, or focal deficit and can progress to intracerebral haemorrhage, typically within the first 1 to 2 weeks after treatment ESVS 2023 · AbuRahma et al. (2022).

30.4Randomised evidence and outcome profiles

Randomized CEA-versus-CAS evidence must be interpreted by symptom status, endpoint and procedural window. CREST’s mixed cohort showed different early hazards: more stroke after CAS and more myocardial infarction after CEA. Similar post-procedural ipsilateral stroke prevention does not establish identical overall stroke outcomes, and these trials do not establish TCAR equivalence. Müller et al. (2020) · Brott et al. (2016) · CREST · 2010

CREST puts numbers on this trade. The 4-year primary composite of periprocedural stroke, MI, or death plus ipsilateral stroke was 7.2% with CAS versus 6.8% with CEA (HR 1.11, not significant). Periprocedural stroke was higher with CAS at 4.1% versus 2.3% (p=0.01), while periprocedural MI was higher with CEA at 2.3% versus 1.1% (p=0.03). Extended follow-up to 10 years showed no significant difference in the primary composite Brott et al. (2016) · CREST · 2010.

Contemporary medical-therapy comparisons address a different question. CREST-2 randomized patients with asymptomatic ≥70% stenosis in two separate trials. Its four-year primary outcome combined stroke or death through day 44 after randomization with subsequent ipsilateral ischemic stroke. Intensive medical management alone versus added transfemoral CAS produced rates of 6.0% versus 2.8% (P=0.02); medical management alone versus added CEA produced 5.3% versus 3.7% (P=0.24). This is not randomized evidence that CAS is superior to CEA, and the CEA result does not prove absence of benefit. Medical Management 2026

ECST-2’s two-year interim report randomized 429 patients with ≥50% stenosis and asymptomatic or selected symptomatic disease with a CAR-predicted five-year ipsilateral-stroke risk below 20%. Adding revascularization did not significantly improve its hierarchical clinical-and-imaging outcome (win ratio 1.01, 95% CI 0.60 to 1.70). Its population, outcome and follow-up differ from CREST-2 and from the established higher-risk symptomatic CEA trials. ECST-2 2025

30.5Areas of controversy

• How contemporary asymptomatic trial results should modify selection under older society recommendations, without treating separate CAS and CEA comparisons as head-to-head evidence Medical Management 2026 · ECST-2 2025.
• The patient-level weighting of the CEA versus CAS composite endpoint, specifically trading a higher early stroke risk with stenting against a higher early myocardial infarction risk with open surgery Brott et al. (2016) · CREST · 2010.
• Which patients benefit from TCAR rather than another route remains incompletely resolved by observational comparisons; device suitability and operator results do not eliminate confounding Effectiveness Transcarotid 2025 · CMS 2023.

Further reading

• Timing of carotid intervention in symptomatic carotid artery stenosis: a topical review. (2023). Symptomatic carotid intervention timing and index-event definitions; topical review. Timing carotid 2023